vTv Therapeutics (NASDAQ:VTVT) Stock Rating Upgraded by Wall Street Zen

vTv Therapeutics (NASDAQ:VTVT) was upgraded by analysts at Wall Street Zen to a “sell” rating in a report released on Saturday.

Other equities analysts have also issued research reports about the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of vTv Therapeutics in a research note on Monday. BTIG Research assumed coverage on vTv Therapeutics in a research note on Wednesday, November 19th. They set a “buy” rating and a $40.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $47.00 price target (up from $36.00) on shares of vTv Therapeutics in a report on Friday, December 19th. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $43.50.

vTv Therapeutics Stock Up 2.4%

NASDAQ:VTVT opened at $37.91 on Friday. The stock has a fifty day simple moving average of $28.68 and a 200 day simple moving average of $21.50. The firm has a market capitalization of $149.37 million, a price-to-earnings ratio of -11.42 and a beta of 0.50. vTv Therapeutics has a 1-year low of $13.15 and a 1-year high of $38.46.

vTv Therapeutics (NASDAQ:VTVT) last posted its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.97) by ($0.11).

Institutional Trading of vTv Therapeutics

A hedge fund recently raised its stake in vTv Therapeutics stock. Baker BROS. Advisors LP lifted its holdings in shares of vTv Therapeutics Inc. (NASDAQ:VTVT) by 52.4% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 148,314 shares of the biotechnology company’s stock after purchasing an additional 51,000 shares during the quarter. Baker BROS. Advisors LP owned approximately 3.77% of vTv Therapeutics worth $3,463,000 as of its most recent SEC filing. 17.51% of the stock is owned by institutional investors.

vTv Therapeutics Company Profile

vTv Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Westport, Connecticut, focused on discovering and developing orally administered small-molecule therapies for chronic diseases. Employing its proprietary medicinal chemistry platform, the company seeks to generate novel compounds that modulate key disease pathways while optimizing safety and pharmacokinetic properties.

The company’s lead candidate, azeliragon (TTP488), is an oral inhibitor of the receptor for advanced glycation end products (RAGE) and has completed Phase II/III clinical evaluation in early-stage Alzheimer’s disease.